Kuethe F, Figulla H R, Voth M, Richartz B M, Opfermann T, Sayer H G, Krack A, Fritzenwanger M, Höffken K, Gottschild D, Werner G S
Klinik für Innere Medizin I, Freiedrich-Schiller-Universität, Jena.
Dtsch Med Wochenschr. 2004 Feb 27;129(9):424-8. doi: 10.1055/s-2004-820061.
Animal data suggest that mobilized bone marrow cells (BMC) may contribute to tissue regeneration after myocardial infarction (MI). However the safety, feasibility and efficacy of treatment with granulocyte colony-stimulating factor (G-CSF) to mobilize BMC after acute myocardial infarction in patients is unknown. We analysed cardiac function and perfusion in 5 patients who were treated with G-CSF in addition to standard therapeutical regimen.
48 h after successful recanalization and stent implantation in 5 patients with acute MI, the patients received 10 micro g/kg bodyweight/day G-CSF subcutaneously for a mean treatment duration of 7.6+/-0.5 days. Peak value of CD34 (+) cells, a multipotent subfraction of bone marrow cells, was reached after 5.0+/-0.7 days. After 3 months of follow-up global left ventricular ejection fraction (determined by radionuclid-ventriculography) increased significantly from 42.2+/-6.6 % to 51.6+/-8.3 % (P<0.05). The wall motion score and the wall perfusion score (determined by ECG gated SPECT) decreased from 13.5+/-3.6 to 9.9+/-3.5 (P<0.05) and from 9.6+/-2.9 to 7.0+/-4.5 (P<0.05), respectively, indicating a significant improvement of myocardial function and perfusion. No severe side effects of G-CSF treatment could be observed. Malignant arrhythmias were not observed either.
In patients with acute MI, treatment with G-CSF to mobilize BMC appears to be well tolerable under clinical conditions. Improved cardiac function and perfusion may be attributed to BMC-associated promotion of myocardial regeneration and neovascularization.
动物数据表明,动员的骨髓细胞(BMC)可能有助于心肌梗死(MI)后的组织再生。然而,粒细胞集落刺激因子(G-CSF)治疗在急性心肌梗死患者中动员BMC的安全性、可行性和疗效尚不清楚。我们分析了5例在标准治疗方案基础上加用G-CSF治疗的患者的心脏功能和灌注情况。
5例急性心肌梗死患者成功再灌注并植入支架后48小时,患者接受皮下注射10μg/kg体重/天的G-CSF,平均治疗持续时间为7.6±0.5天。骨髓细胞多能亚群CD34(+)细胞的峰值在5.0±0.7天后达到。随访3个月后,整体左心室射血分数(通过放射性核素心室造影测定)从42.2±6.6%显著增加至51.6±8.3%(P<0.05)。壁运动评分和壁灌注评分(通过心电图门控单光子发射计算机断层扫描测定)分别从13.5±3.6降至9.9±3.5(P<0.05)和从9.6±2.9降至7.0±4.5(P<0.05),表明心肌功能和灌注有显著改善。未观察到G-CSF治疗的严重副作用。也未观察到恶性心律失常。
在急性心肌梗死患者中,临床条件下G-CSF治疗动员BMC似乎耐受性良好。心脏功能和灌注的改善可能归因于BMC相关的心肌再生和新生血管形成促进作用。